Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2019 · 10-Q
Revenue$41.96K$41.96K−4.6% vs Q3 2018 Net Income-$487.07K-$487.07KN/M vs Q3 2018 EPS Diluted$0.00$0.00— vs Q3 2018 Gross Profit$35,467+440.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$151,235N/M Margins · derivedGross margin84.5%+69.6 pt vs Q3 2018
Operating margin-560.5%+1382.5 pt vs Q3 2018
Net margin-1160.7%+1040.8 pt vs Q3 2018
ended Sep 30, 2019 · filed May 14, 2021 · 592 d after period end